Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort

Peyronnet, B.; Vurture, Gregory; Palma, Jose‐Alberto; Malacarne, Dominique R.; Feigin, Andrew; Sussman, Rachael D.; Biagioni, Milton; Palmerola, Ricardo; Gilbert, Rebecca M.; Rosenblum, Nirit; Frucht, Steven J.; Kaufmann, Horacio; Νitti, Victor W.; Brucker, Benjamin M.

doi:10.1016/j.parkreldis.2018.07.005

Cited by 39 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three patients started to use β3 adrenoceptor agonist because β3 adrenoceptor agonist was commercially available only after DBS surgery in some patients, which made the interpretation of the present result complicated. Although the effect of β3 adrenoceptor agonist on the urinary symptoms in PD is not fully understood, recent retrospective study suggested that 50% of PD patients reported improvement in OAB after administration of β3 adrenoceptor agonist (Peyronnet et al, ). Because only three patients started to use β3 adrenoceptor agonist after DBS, the administration of β3 adrenoceptor agonist might have only subtle effects on overall results of this study.…”

Section: Discussionmentioning

confidence: 99%

Urinary symptoms are correlated with quality of life after deep brain stimulation in Parkinson's disease

et al. 2018

View full text Add to dashboard Cite

AimsDeep brain stimulation (DBS) is known to dramatically improve motor complications in patients with Parkinson's disease (PD), but its effect on urinary symptoms and health‐related quality of life (HRQOL) remains unknown. We aimed to examine the relationship between urinary symptoms and HRQOL in patients with PD who underwent DBS.MethodsThe International Prostate Symptom Score (IPSS) and overactive bladder symptom score (OABSS) were determined to evaluate urinary symptoms in patients with PD who underwent DBS. Postoperative evaluations were performed at 3 months, 1 year, and 3 years postoperatively. We also performed a urodynamic study (UDS) in 13 patients with PD preoperatively and postoperatively. A follow‐up UDS was performed 2.0 ± 0.5 years postoperatively.ResultsThe preoperative urinary symptoms questionnaire was completed by 28 patients, of whom 14 completed the postoperative urinary symptoms questionnaire after 3 months, 18 after 1 year, and 10 after 3 years. The mean OABSS and IPSS did not change significantly at any follow‐up periods postoperatively. When assessing the relationship between urinary symptoms and HRQOL and motor functions, the OABSS and IPSS showed significant positive correlations with HRQOL at 3 months postoperatively. The OABSS and IPSS showed significant positive correlations with activities of daily living (ADL) during the off‐phase at 3 years postoperatively. All urodynamic parameters remained unchanged postoperatively.ConclusionsDeep brain stimulation did not significantly affect urinary dysfunctions in patients with PD. Urinary symptoms might partially contribute to HRQOL at 3 months postoperatively and ADL during the off‐phase at 3 years postoperatively.

show abstract

Section: Discussionmentioning

confidence: 99%

Urinary symptoms are correlated with quality of life after deep brain stimulation in Parkinson's disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…An alternative drug without cognitive side effects is mirabegron, a beta 3-adrenoceptor agonist; a retrospective cohort study which considered 50 patients between 2012 and 2017 suggested this agent was well tolerated in PD and offered benefit. 88…”

Section: Urinary Symptomsmentioning

confidence: 99%

New evidence on the management of Lewy body dementia

Taylor

McKeith

Burn

et al. 2020

The Lancet Neurology

216

274

View full text Add to dashboard Cite

Dementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia (LBD), are common neurodegenerative conditions. Patients with LBD present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. The expression of these varies between individual patients, and over time. Treatments may benefit one symptom, but at the expense of worsening another, making management difficult. Often symptoms are managed in isolation and by different specialists, which undermines high quality care.Clinical trials and meta-analyses now provide an improved evidence base for the treatment of cognitive, neuropsychiatric and motor symptoms in LBD, in addition to which expert consensus opinion supports the application of treatments from related conditions such as Parkinson's disease (PD) for the management of, for example, autonomic symptoms. There remain however clear evidence gaps and there is a high need for future clinical trials focused on specific symptoms in LBD.

show abstract

“…58 Studies suggest that mirabegron is efficacious in patients with Parkinson's disease, MS, and SCI, with tolerable side effect profiles. [59][60][61] Desmopressin Desmopressin, a synthetic analogue of arginine vasopressin, promotes fluid re-absorption at the distal and collecting tubules of the kidney and thereby temporarily reduces urine production and volume-related detrusor overactivity. It is useful for the treatment of urinary frequency or nocturia in patients with MS, providing symptom relief for up to 6 hours.…”

Section: Beta-3-adrenergic Receptor Agonistsmentioning

confidence: 99%

Neurogenic Bladder: Epidemiology, Diagnosis, and Management

Panicker

2020

Semin Neurol

View full text Add to dashboard Cite

Lower urinary tract dysfunction is a common sequel of neurological disease resulting in symptoms that significantly impacts quality of life. The site of the neurological lesion and its nature influence the pattern of dysfunction. The risk for developing upper urinary tract damage and renal failure is considerably lower in patients with slowly progressive nontraumatic neurological disorders, compared with those with spinal cord injury or spina bifida. This acknowledged difference in morbidity is considered when developing appropriate management algorithms. The preliminary evaluation consists of history taking, and a bladder diary and may be supplemented by tests such as uroflowmetry, post-void residual measurement, renal ultrasound, (video-)urodynamics, neurophysiology, and urethrocystoscopy, depending on the clinical indications. Incomplete bladder emptying is most often managed by intermittent catheterization, and storage dysfunction is managed by antimuscarinic medications. Intra-detrusor injections of onabotulinumtoxinA have revolutionized the management of neurogenic detrusor overactivity. Neuromodulation offers promise for managing both storage and voiding dysfunction. In select patients, reconstructive urological surgery may become necessary. An individualized, patient-tailored approach is required for the management of lower urinary tract dysfunction in this special population.

show abstract

Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort

Cited by 39 publications

References 24 publications

Urinary symptoms are correlated with quality of life after deep brain stimulation in Parkinson's disease

Urinary symptoms are correlated with quality of life after deep brain stimulation in Parkinson's disease

New evidence on the management of Lewy body dementia

Neurogenic Bladder: Epidemiology, Diagnosis, and Management

Contact Info

Product

Resources

About